Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743519 | 0.93 | ALOX15 (0.68) | ALOX15TOP2AKMT2AALDH1A1AKR1C3 | |
| SCHEMBL6742473 | 0.88 | ALOX15 (0.56) | ALOX15LDHATOP2ALTA4HAKR1C3 | |
| SCHEMBL31321672 | 0.87 | ALOX15 (0.64) | ALOX15LDHATOP2APTGS1KMT2A | |
| SCHEMBL13349764 | 0.87 | ALOX15 (0.64) | ALOX15LDHATOP2APTGS1KMT2A | |
| SCHEMBL2817244 | 0.85 | ALOX15 (0.62) | ALOX15LDHAKMT2AALDH1A1LTA4H | |
| SCHEMBL8386812 | 0.85 | ALOX15 (0.62) | ALOX15LDHATOP2APTGS1KMT2A | |
| SCHEMBL20095268 | 0.84 | ALOX15 (0.61) | ALOX15LDHATOP2APTGS1KMT2A | |
| SCHEMBL6742916 | 0.83 | ALOX15 (0.52) | ALOX15KMT2AALDH1A1 | |
| SCHEMBL3612351 | 0.83 | ALOX15 (0.59) | ALOX15LDHATOP2APTGS1KMT2A | |
| SCHEMBL21976826 | 0.83 | ALOX15 (0.53) | ALOX15TOP2ALTA4HAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | ALOX15 622/4885LDHA 3416/4885TOP2A 1909/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | ALOX15 327/4885LDHA 1936/4885TOP2A 4225/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | ALOX15 598/4885LDHA 3549/4885TOP2A 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.